<DOC>
	<DOCNO>NCT00449761</DOCNO>
	<brief_summary>This study evaluate efficacy safety LBH589B adult patient chronic myeloid leukemia accelerate phase blast phase ( blast crisis ) resistant disease follow treatment least two BCR-ABL tyrosine kinase inhibitor</brief_summary>
	<brief_title>Efficacy Safety LBH589B Adult Patients With Refractory Chronic Myeloid Leukemia ( CML ) Accelerated Phase Blast Phase ( Blast Crisis )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Inclusion criterion : Male female patient age ≥ 18 year old Diagnosis Philadelphia chromosome positive accelerate blast phase chronic myeloid leukemia define : Accelerated phase presence least one following : ≥15 % &lt; 30 % blast blood bone marrow ≥30 % blast plus promyelocytes peripheral blood bone marrow ( provide &lt; 30 % blast present bone marrow ) ≥ 20 % basophile peripheral blood Thrombocytopenia &lt; 100 X 109 /L unrelated therapy Blast phase ( blast crisis ) presence one following : ≥ 30 % blast blood , marrow Extramedullary infiltrates leukemic cell Prior treatment least two BCRABL tyrosine kinase inhibitor ( i.e. , imatinib , nilotinib , dasatinib ) demonstrate resistance recent kinase inhibitor therapy . Patients history intolerance one BCRABL kinase inhibitor ( defined discontinuation treatment due grade 3 4 adverse event related treatment ) consider eligible enter study demonstrate resistance recent BCRABL kinase inhibitor . Patients must adequate laboratory value : Baseline measurement leave ventricular ejection fraction [ assessment heart ability pump effectively ] Assessment patient ability perform every day activity . Assessment ECOG [ Eastern Cooperative Oncology Group ] Performance Status Exclusion criterion : A candidate hematopoitic stem cell transplantation Prior therapy certain medication Patients chronic phase chronic myeloid leukemia Impaired cardiac function clinically significant cardiac disease Concomitant use drug risk possible risk cause QTc prolongation torsades de pointes Concomitant use certain medication Impairment GI function GI disease Patients unresolved diarrhea Patients receive chemotherapy , investigational drug ( BCRABL tyrosine kinase inhibitor ) undergo major surgery &lt; 4 week prior start study drug recover side effect therapy Patients receive BCRABL tyrosinekinase inhibitor within 1 week first treatment LBH589 Women pregnant breast feed woman childbearing potential use effective method birth control Male patient whose sexual partner woman child bear potential use effective birth control Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Refractory</keyword>
	<keyword>Chronic Myeloid</keyword>
	<keyword>Leukemia</keyword>
	<keyword>accelerate phase</keyword>
	<keyword>blast phase ( blast crisis )</keyword>
	<keyword>adult</keyword>
	<keyword>oral LBH589</keyword>
</DOC>